Grant-Funded Research
From Office of Health Economics
Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).
Access Statistics for this working paper series.
Is something missing from the series or not right? See the RePEc data check for the archive and series.
- 002525: Capturing the lived experiences of informal care in acute leukemia

- Samantha Nier, Claud Theakston, Priscila Radu, David Mott and Nadine Henderson
- 002522: Patient preferences for treatment in relapsed/refractory acute leukemia

- David Mott, Hannah Hussain, Jake Hitch, Sulayman Chowdhury, Samantha Nier and Chris Skedgel
- 002521: The commercial case for investing in ALS

- Brittany Darrow, Priscila Radu and Amanda Cole
- 002518: Understanding the preferences of people with acute leukemia for different health outcomes

- David Mott, Hannah Hussain, Sulayman Chowdhury, Samantha Nier and Chris Skedgel
- 002484: Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy

- Nadine Henderson;George Bray;Chris Skedgel
- 002482: 2022 OHE Annual Report to the Charity Commission

- Office of Health Economics
- 002472: 2021 OHE Annual Report to the Charity Commission

- Mireia Jofre-Bonet
- 002323: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

- Patricia Cubi-Molla;David Mott;Nadine Henderson;Martina Garau;Bernarda Zamora;Mendel Grobler
- 002308: Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?

- Christopher Sampson
- 002298: Cornerstones of “Fair” Drug Coverage: Appropriate Cost - Sharing and Utilization Management Policies for Pharmaceuticals

- Steven D Pearson;Maria Lowe;Celia S. Segal;Chris Henshall;Adrian Towse
- 002187: The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

- Niklas Wallin-Bernhardsson;Peter Lindgren;Mikel Berdud;Bernarda Zamora;Adrian Towse
- 002184: Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

- Koonal Shah;Juan Manuel Ramos-Goñi;Nancy Devlin;Oliver Rivero-Arias
- 002154: The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

- Simon Brassel;Olga Rozanova;Adrian Towse
- 002150: The Future of Global Health Procurement: Issues around Pricing Transparency

- Mikel Berdud;Adrian Towse;Kalipso Chalkidou;Emma Dean;Jimena Ferraro;Lou Garrison;Cassandra Nemzoff
- 002142: Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

- Karla Hernandez-Villafuerte;Yan Feng;David Parkin;Nancy Devlin;Bernarda Zamora;Adrian Towse
- 002094: Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA

- Nancy Devlin;Paula Lorgelly;Mike Herdman
- 002044: Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

- Bernarda Zamora;Adrian Towse;Karla Hernandez-Villafuerte
- 002040: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

- Christopher Sampson
- 002036: Establishing a Reasonable Price for an Orphan Drug

- Michael F. Drummond;Mikel Berdud;Adrian Towse
- 001984: New Methods for Analysing the Distribution of EQ-5D Observations

- David Parkin;Yan Feng;Andrew Bateman;Mike Herdman;Nancy Devlin;Bernarda Zamora
- 001871: Why Do Immigrants Report Lower Life Satisfaction?

- Firat Yaman;Patricia Cubi-Molla
- 001798: What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?

- Nancy Devlin;Koonal Shah;Ken Buckingham
- 001777: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

- Aurea Duran;Nancy Devlin;Phill O’Neill;Amanda Cole
- 001764: Uncertainty and Risk in HTA Decision Making

- Paul Barnsley;Adrian Towse;Patricia Cubi-Molla
- 001756: The Distribution of the EQ-5D-5L Index in Patient Populations

- Bernarda Zamora;Yan Feng;Nancy Devlin;Andrew Bateman;David Parkin
- 001679: New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data

- Yan Feng;Nancy Devlin;Koonal Shah;Brendan Mulhern;Ben van Hout
- 001678: Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England

- Nancy Devlin;Koonal Shah;Yan Feng;Berndan Mulhern;Ben Van Hout
- 001669: Model of Behaviour within Fuzzy Budget Constraints

- Office of Health Economics
- 001632: Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations

- Michele Pistollato
- 000517: Opportunity Costs of Implementing NICE Decisions in NHS Wales

- Sarah Karlsberg-Schaffer;Jon Sussex;Dyfrig Hughs;Nancy Devlin
- 000175: The Effect of an Increase in the Rate of Payment on General Practitioner's Intrinsic and Extrinsic Motivation

- Yan Feng;Shelley Farrar;Matt Sutton;Ada May
- 000172: Valuing Health at the End of Life: An Exploratory Preference Elicitation Study

- Koonal Shah;Aki Tsuchiya;Allan Wailoo
- 000126: Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity

- Koonal Shah;Nancy Devlin
- 000037: Exploring the link between health and wealth in decision making

- Koonal Shah;Priya Sharma;Martina Garau;Adrian Towse